Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

CHICAGO, January 22, 2026--(BUSINESS WIRE)--Relation Insurance Services ("Relation") announced today their acquisition of the assets of PT Business Solutions. The transaction went into effect on ...

South Africa’s post-1994 foreign policy foundations established non-alignment, constitutional adherence and human rights as central principles guiding Pretoria’s relations with other states. However, ...

The California chapter of the largest Muslim charity in the US may lose its tax exempt status over its organization of anti-Israel protests, The Post has learned. The powerful tax-writing Ways and ...

Whether you’re looking to argue better or have a little more fun with your partner, we’ve got you covered. By Jancee Dunn and Catherine Pearson Most couples — even the unicorns among us who claim they ...

Between February 2001 and March 2002, Gary McKinnon says he accessed unsecured U.S. government computers and found a document titled “non-terrestrial officers.” He claimed it listed “fleet-to-fleet ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...